HUMATROPE 36 I.U. (12 mg )

Active substance
Somatropin * (Somatropin )
The Latin name of the drug Humatrope
Humatrope
ATC:
H01AC01 Somatropin
Therapeutic
Hormones of the hypothalamus, pituitary and their antagonists
Nosological classification (ICD-10)
Stunting E34.3 [dwarfism] nec
Q96 Turner's syndrome
Structure and composition
Lyophilized powder for injection in vials of 4 IU, together with the solvent into the vial with 2 ml or excipients for injectable pens Humatropen II 18 and 36 IU / ml, together with a solvent.
Features
Biosynthetic recombinant human growth hormone polypeptide chain comprises amino acid residue 191 (in the sequence identity with human growth hormone).
Pharmacological Action
Mode of action - anabolic hyperglycemia.
Stimulates bone growth, increases the number and size of muscle cells, mobilized fat slows sodium, potassium, phosphorus.
Indications drug Humatrop ™
Growth disturbance with growth hormone deficiency, Turner syndrome.
Contraindications
Hypersensitivity (including m-cresol and glycerin) closed epiphyseal tumor active process, carrying out the anti-tumor therapy, signs of tumor growth of acute intracranial injury period.
Side effects of the drug Humatrop ™
Hyperglycemia, impaired glucose tolerance, Syndrome transient edema symptoms of hypothyroidism.
Cooperation
Glucocorticoids weaken effect.
Dosing and Administration
V / M, N / A. The dosage and timing of administration selected individually (0.48 IU / kg per week). When growth hormone deficiency - 0.48 IU / kg per week in syndrome Turner - 0.8-0.9 IU / kg, equivalent to 24-28 IU / m body surface area weekly. Weekly dose is divided into 6-7 injections and administered in the evening. During long-term treatment, it is necessary to control the concentration of glucose in blood and the thyroid hormones.
Storage conditions of the drug Humatrop ™
List B :. At 2-8 ° C. The resulting solution is stable for 21 days at 2-8 ° C Do not freeze.
Shelf life Humatrop ™
2 years